Storys aus Bad Vilbel
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- Ein Dokumentmehr
Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Ein DokumentmehrPress Release : STADA brings in Henshaw from Biogen to head Specialty as Kim leads Western Europe
Ein DokumentmehrPress Release: STADA’s continued, resilient growth leads to record earnings in Q1
Ein Dokumentmehr- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
Ein Dokumentmehr Press Release: STADA sets course for the future - experienced healthcare manager Andreas Fibig to become Chairman of the Board
Ein Dokumentmehr
Press Release: STADA welcomes Ingo Schachel as Head of Investor Relations
Ein DokumentmehrPress release: STADA continues strong growth journey in the first half of 2024
Ein DokumentmehrPress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
Ein DokumentmehrPress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
Ein DokumentmehrPress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Ein DokumentmehrPress release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
Ein Dokumentmehr
Press release: STADA continues with double-digit sales and profit growth in 2023
Ein DokumentmehrPress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Ein DokumentmehrPress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
Ein Dokumentmehr- 3
Press release: STADA further improves Sustainability ranking; rates among top 6% of pharma players globally
Ein Dokumentmehr Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio
Ein Dokumentmehr- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr